Printer Friendly

Aptar wins FDA approval for needle-free rescue treatment for severe hypoglycemia.

M2 EQUITYBITES-July 26, 2019-Aptar wins FDA approval for needle-free rescue treatment for severe hypoglycemia


Drug delivery company AptarGroup Inc (NYSE:ATR) reported on Thursday the receipt of US Food and Drug Administration (FDA) approval for its Unidose Powder System, an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes.

This is the first FDA approval of a prescription drug using Aptar's patented Unidose Powder System and is Aptar's first combination of a drug delivery device with a protective active packaging container.

According to the company, the Unidose Powder System is a single-use, ready-to-use one-step nasal delivery device which can deliver a powder formulation in an emergency situation quickly and easily. During such an event, the patient or caregiver presses a small plunger on the bottom of the device to release the drug in a single powder puff into the nose, where the drug can be quickly absorbed via the nasal mucosa.

The product is an alternative to injectable kits that may require assembly, including a multistep, time-consuming process of mixing powder and liquid.

((Comments on this story may be sent to

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jul 26, 2019
Previous Article:Universal Logistics Holdings reports 12.9% higher net income for Q2 and dividend of USD0.105 per share.
Next Article:Virginia Bio hires John Newby as CEO.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters